Edgestream Partners L.P. Increases Stock Holdings in Cencora, Inc. $COR

Edgestream Partners L.P. lifted its stake in shares of Cencora, Inc. (NYSE:COR) by 1,348.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,237 shares of the company’s stock after purchasing an additional 11,392 shares during the quarter. Edgestream Partners L.P.’s holdings in Cencora were worth $3,669,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Atlantic Edge Private Wealth Management LLC raised its position in Cencora by 70.0% during the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after buying an additional 35 shares during the last quarter. Costello Asset Management INC acquired a new position in shares of Cencora during the first quarter worth about $28,000. Vermillion & White Wealth Management Group LLC raised its holdings in Cencora by 69.4% during the second quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock worth $31,000 after purchasing an additional 43 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in Cencora in the second quarter valued at about $61,000. Finally, ANTIPODES PARTNERS Ltd purchased a new stake in Cencora in the 2nd quarter valued at approximately $61,000. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

COR has been the subject of a number of analyst reports. JPMorgan Chase & Co. increased their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. UBS Group increased their price objective on Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research report on Friday, November 7th. Wells Fargo & Company raised their target price on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Robert W. Baird upped their price target on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research note on Thursday, November 6th. Finally, Wall Street Zen cut shares of Cencora from a “buy” rating to a “hold” rating in a research note on Friday, November 28th. Eight research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Cencora presently has an average rating of “Moderate Buy” and an average target price of $371.09.

Insider Activity at Cencora

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares of the company’s stock, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 46,640 shares of company stock valued at $14,099,338 over the last 90 days. Insiders own 10.80% of the company’s stock.

Cencora Trading Down 4.5%

Shares of COR stock opened at $334.89 on Thursday. The stock has a market cap of $64.93 billion, a P/E ratio of 42.12, a P/E/G ratio of 1.71 and a beta of 0.63. The company has a quick ratio of 0.55, a current ratio of 0.90 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $377.54. The business has a fifty day simple moving average of $338.63 and a 200-day simple moving average of $308.96.

Cencora (NYSE:COR) last released its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.48% and a return on equity of 227.15%. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the firm earned $3.34 EPS. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts forecast that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Stockholders of record on Friday, November 14th were paid a dividend of $0.60 per share. This is a positive change from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s dividend payout ratio is 30.19%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.